Kinostat®
Protecting diabetic dogs from cataracts and dry eye
Kinostat® is a patented eye drop formulation developed to help prevent diabetic eye complications in dogs by blocking the sorbitol pathway that drives lens and corneal damage.
Overview
Kinostat® at a glance
Eye Drops
Patented ophthalmic formulation for diabetic eye protection.
For Dogs
Developed for diabetic dogs at risk of cataracts and dry eye.
For Dogs
Developed for diabetic dogs at risk of cataracts and dry eye.
Near Launch
Positioned for 2026 launch pending final CMC completion.
Near Launch
Positioned for 2026 launch pending final CMC completion.
Sorbitol Block
Targets the pathway linked to diabetic ocular damage.
Sorbitol Block
Targets the pathway linked to diabetic ocular damage.
Science
How it works
Kinostat is an aldose reductase inhibitor designed to reduce sorbitol buildup in the eye, helping protect both the lens and ocular surface from diabetic damage.
Blocks conversion of glucose into sorbitol
Helps reduce osmotic lens stress linked to cataracts
Supports corneal health and tear production
Targets diabetic damage before it progresses
Designed for long-term vision protection
Benefits
What it protects
Cataract Risk
Helps reduce the likelihood of cataract formation in diabetic dogs.
Cataract Risk
Helps reduce the likelihood of cataract formation in diabetic dogs.
Tear Health
Supports protection against dry eye disease linked to diabetes.
Tear Health
Supports protection against dry eye disease linked to diabetes.
Vision Support
Aims to preserve long-term eyesight and reduce later complications.
Vision Support
Aims to preserve long-term eyesight and reduce later complications.
Proof
Development progress and validation
Kinostat combines clinical evidence, regulatory momentum, and a defined path to commercialization.
Clinical trial data showed strong reduction in cataract development
Clinical trial data also showed reduced dry eye risk
Provisional FDA approval received under MUMS designation
Final CMC procedures remain in progress
Veterinary launch is targeted for 2026 with funding
Human development is planned after veterinary entry
Want to learn more about our products?
Contact us to learn more about our ophthalmic and neuroprotective product portfolio.
Want to learn more about our products?
Contact us to learn more about our ophthalmic and neuroprotective product portfolio.
Want to learn more about our products?
Contact us to learn more about our ophthalmic and neuroprotective product portfolio.